Browse EBF2

Summary
SymbolEBF2
Nameearly B-cell factor 2
Aliases FLJ11500; COE2; EBF-2; O/E-3; OE-3; Collier, Olf and EBF 2; OLF-1/EBF-LIKE 3; metencephalon-mesencephalnon-o ......
Chromosomal Location8p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF16422 Transcription factor COE1 DNA-binding domain
PF16423 Transcription factor COE1 helix-loop-helix domain
PF01833 IPT/TIG domain
Function

Transcription factor that, in osteoblasts, activates the decoy receptor for RANKL, TNFRSF11B, which in turn regulates osteoclast differentiation. Acts in synergy with the Wnt-responsive LEF1/CTNNB1 pathway. Recognizes variations of the palindromic sequence 5'-ATTCCCNNGGGAATT-3' (By similarity).

> Gene Ontology
 
Biological Process GO:0001709 cell fate determination
GO:0035561 regulation of chromatin binding
GO:0035563 positive regulation of chromatin binding
GO:0045165 cell fate commitment
GO:0045444 fat cell differentiation
GO:0050873 brown fat cell differentiation
GO:0051098 regulation of binding
GO:0051099 positive regulation of binding
GO:0060612 adipose tissue development
GO:0061448 connective tissue development
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolEBF2
Nameearly B-cell factor 2
Aliases FLJ11500; COE2; EBF-2; O/E-3; OE-3; Collier, Olf and EBF 2; OLF-1/EBF-LIKE 3; metencephalon-mesencephalnon-o ......
Chromosomal Location8p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EBF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolEBF2
Nameearly B-cell factor 2
Aliases FLJ11500; COE2; EBF-2; O/E-3; OE-3; Collier, Olf and EBF 2; OLF-1/EBF-LIKE 3; metencephalon-mesencephalnon-o ......
Chromosomal Location8p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EBF2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEBF2
Nameearly B-cell factor 2
Aliases FLJ11500; COE2; EBF-2; O/E-3; OE-3; Collier, Olf and EBF 2; OLF-1/EBF-LIKE 3; metencephalon-mesencephalnon-o ......
Chromosomal Location8p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EBF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4840.0809
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4460.363
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5060.216
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.2590.00708
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.7030.191
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7060.626
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1010.861
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1720.851
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1140.903
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5050.564
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.7530.1
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1710.44
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EBF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.84.110.70.0828
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.85.19.70.199
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211733.317.615.70.46
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.5037.50.209
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.827.33.51
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.2013.20.0705
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.2018.20.274
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEBF2
Nameearly B-cell factor 2
Aliases FLJ11500; COE2; EBF-2; O/E-3; OE-3; Collier, Olf and EBF 2; OLF-1/EBF-LIKE 3; metencephalon-mesencephalnon-o ......
Chromosomal Location8p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EBF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEBF2
Nameearly B-cell factor 2
Aliases FLJ11500; COE2; EBF-2; O/E-3; OE-3; Collier, Olf and EBF 2; OLF-1/EBF-LIKE 3; metencephalon-mesencephalnon-o ......
Chromosomal Location8p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EBF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EBF2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEBF2
Nameearly B-cell factor 2
Aliases FLJ11500; COE2; EBF-2; O/E-3; OE-3; Collier, Olf and EBF 2; OLF-1/EBF-LIKE 3; metencephalon-mesencephalnon-o ......
Chromosomal Location8p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EBF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEBF2
Nameearly B-cell factor 2
Aliases FLJ11500; COE2; EBF-2; O/E-3; OE-3; Collier, Olf and EBF 2; OLF-1/EBF-LIKE 3; metencephalon-mesencephalnon-o ......
Chromosomal Location8p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EBF2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEBF2
Nameearly B-cell factor 2
Aliases FLJ11500; COE2; EBF-2; O/E-3; OE-3; Collier, Olf and EBF 2; OLF-1/EBF-LIKE 3; metencephalon-mesencephalnon-o ......
Chromosomal Location8p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EBF2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEBF2
Nameearly B-cell factor 2
Aliases FLJ11500; COE2; EBF-2; O/E-3; OE-3; Collier, Olf and EBF 2; OLF-1/EBF-LIKE 3; metencephalon-mesencephalnon-o ......
Chromosomal Location8p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EBF2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.